Related Experiment Video
Updated: Feb 14, 2026

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
Safety evaluation of a human chimeric monoclonal antibody that recognizes the extracellular loop domain of claudin-2
Yosuke Hashimoto1, Tomoyuki Hata1, Minoru Tada2
1Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan.
Abstract:
Claudin-2 (CLDN-2), a pore-forming tight junction protein with a tetra-transmembrane domain, is involved in carcinogenesis and the metastasis of some cancers. Although CLDN-2 is highly expressed in the tight junctions of the liver and kidney, whether CLDN-2 is a safe target for cancer therapy remains unknown. We recently generated a rat monoclonal antibody (mAb, clone 1A2) that recognizes the extracellular domains of human and mouse CLDN-2. Here, we investigated the safety of CLDN-2-targeted cancer therapy by using 1A2 as a model therapeutic antibody. Because most human therapeutic mAbs are IgG1 subtype that can induce antibody-dependent cellular cytotoxicity, we generated a human-rat chimeric IgG1 form of 1A2 (xi-1A2). xi-1A2 activated Fcγ receptor IIIa in the presence of CLDN-2-expressing cells, indicating that xi-1A2 likely exerts antibody-dependent cellular cytotoxicity. At 24 h after its intravenous injection, xi-1A2 was distributed into the liver, kidney, and tumor tissues of mice bearing CLDN-2-expressing fibrosarcoma cells. Treatment of the xenografted mice with xi-1A2 attenuated tumor growth without apparent adverse effects, such as changes in body weight and biochemical markers of liver and kidney injury. These results support xi-1A2 as the lead candidate mAb for safe CLDN-2-targeted cancer therapy.
Insights
Claudin-2 (CLDN-2) is a potential cancer target. A novel antibody (xi-1A2) targeting CLDN-2 showed promising results in reducing tumor growth without causing significant adverse effects in preclinical models.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Claudin-2 (CLDN-2) is a tight junction protein implicated in cancer progression.
- CLDN-2 expression in liver and kidney raises safety concerns for targeted therapies.
- A rat monoclonal antibody (mAb), clone 1A2, targeting CLDN-2 extracellular domains was previously developed.
Purpose of the Study:
- To evaluate the safety and efficacy of CLDN-2-targeted cancer therapy using the 1A2 mAb as a model.
- To generate a chimeric IgG1 antibody (xi-1A2) for potential antibody-dependent cellular cytotoxicity (ADCC).
Main Methods:
- Generated a human-rat chimeric IgG1 antibody (xi-1A2) from clone 1A2.
- Assessed xi-1A2's ability to activate Fcγ receptor IIIa.
- Investigated xi-1A2 biodistribution in mice bearing CLDN-2-expressing fibrosarcoma.
- Evaluated tumor growth and potential adverse effects following xi-1A2 treatment.
Main Results:
- Xi-1A2 demonstrated Fcγ receptor IIIa activation in the presence of CLDN-2-expressing cells, suggesting ADCC potential.
- Intravenous injection of xi-1A2 led to its distribution in liver, kidney, and tumor tissues.
- Treatment with xi-1A2 significantly attenuated tumor growth in xenografted mice.
- No apparent adverse effects were observed, including changes in body weight or liver/kidney injury markers.
Conclusions:
- Xi-1A2 is a promising candidate for safe CLDN-2-targeted cancer therapy.
- The study supports CLDN-2 as a viable therapeutic target with acceptable safety profile.
More Related Videos
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
12:43Enrichment and Purging of Human Embryonic Stem Cells by Detection of Cell Surface Antigens Using the Monoclonal Antibodies TG30 and GCTM-2
Published on: December 6, 2013
Related Concept Videos
Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
Survey Safety
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Three Developmental Domains
Physical Development
Physical processes, also known as maturation, encompass the biological changes that occur across an individual's life. These changes begin with genetic inheritance and continue through various stages, including growth in height and weight,...
Membrane Domains
Protein Domains
The membrane comprises a group of distinct proteins responsible for carrying out a cell's specific function. For example, the plasma membrane of the human sperm, or a single germ cell, contains a unique set of proteins in the...
Three-Domain System of Life